Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OPN-375 · 4 trials · 3 indications
The CSS consists of the sum of the scores (0-3) assigned to each of the following symptoms of CRS: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The total CSS for each day can range from 0 to 9. Participants will report symptom severity immediately preceding the time of scoring every morning (AM). The baseline CSS is the average of the CSS's over the last 7 days of the single-blind run-in period. The end of Week 4 CSS is the average of the CSS's over the 7 days before Week 4.
Change from baseline to the end of Week 4 in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Baseline scores are the averaged total instantaneous AM scores over the last 7 days of the single blind run in period, and the end of Week 4, scores are averaged over the 7 days from the subject diary. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. Composite score is a sum of the 3 symptom scores and will range from 0 to 9.
Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT. Percent volume opacified can range from 0% to 100%. Outcome measure is the percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.
Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.
Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT. Percent volume opacified can range from 0% to 100%. Outcome measure is the percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.
| Arm | Type | Description |
|---|---|---|
| Placebo BID | PLACEBO_COMPARATOR | Double-Blind Treatment Phase: Intranasal administration of matching placebo BID x 12 weeks |
| OPN-375 186 µg BID | ACTIVE_COMPARATOR | Double-Blind Treatment Phase: Intranasal administration of OPN-375 186 µg x 12 weeks |
| OPN-375 186 μg BID | ACTIVE_COMPARATOR | OPN-375 186 μg BID x 24 Weeks |
| OPN-375 372 μg BID | ACTIVE_COMPARATOR | OPN-375 372 μg BID x 24 Weeks |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo BID x 24 Weeks |
| Name | Type | Description |
|---|---|---|
| OPN-375 | DRUG | OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID |
| Placebo | DRUG | Placebo solution administered via exhalation delivery system (EDS). |
Inclusion Criteria: 1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening) 2. Female subjects, if sexually active, must: 1. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patc...
OPN-375 is an investigational small molecule being developed for chronic rhinosinusitis, chronic rhinosinusitis without nasal polyps, and bilateral nasal polyposis. It is administered as an intranasal spray and is currently in Phase 3 clinical trials for these ENT conditions.
OPN-375 is being developed by OptiNose, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol OPTN. The company is conducting Phase 3 clinical trials to evaluate the drug's efficacy and safety in patients with chronic rhinosinusitis and nasal polyps.
OPN-375 is in Phase 3 clinical development. It is not FDA approved and remains investigational. Multiple Phase 3 trials are ongoing or completed, including studies in adolescents and adults with chronic rhinosinusitis with or without nasal polyps.
OPN-375 has been studied in several Phase 3 trials. NCT03747458 evaluated efficacy and safety in adolescents with bilateral nasal polyps. NCT03781804 and NCT03960580 studied adults with chronic rhinosinusitis with or without nasal polyps. NCT06850805 is currently recruiting adolescents with chronic rhinosinusitis without nasal polyps.
OPN-375 is a distinct investigational drug developed by OptiNose. It is not known to be the same as any other marketed product. Its mechanism of action is not disclosed in available information, and it is being studied specifically for chronic rhinosinusitis and nasal polyposis.